small molecule

ENTEREG

ALVIMOPAN

Loss of exclusivityFebruary 2030latest FDA-listed patent expiry
CompanyCubist PharmaceuticalsSee this company's full patent-cliff portfolio

Drug detail

Brand nameENTEREG
Active ingredientALVIMOPAN
Strength12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2008
Marketing statusDISCN

Listed patents

PatentExpiresType
8946262February 2030use U-1655

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ENTEREG patent cliff — loss of exclusivity February 2030 | CliffBio